Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Inclusion Criteria

• •Participants chronically infected with HCV Genotype 4
• •HCV RNA viral load of ≥ 10,000 IU/mL
• •No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent
• •Results of a liver biopsy obtained within three years prior to enrollment to demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are permitted, however, and any prior biopsy is permitted